IL-33 regulates TNF-α dependent effects in synovial fibroblasts

International Journal of Molecular Medicine

Volumn 29, Issue 4, 2012, Pages 530-540

  Kunisch, Elke ^a   Chakilam, Saritha ^a,b   Gandesiri, Muktheshwar ^a,b   Kinne, Raimund W ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Fibroblasts; Inflammatory diseases; Interleukin 33; TNF

Indexed keywords

INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RNA; STROMELYSIN; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE PRODUCTION; DOWN REGULATION; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CHEMOKINE CCL2; DOWN-REGULATION; FIBROBLASTS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858215590     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.883     Document Type: Article

References (39)

1. Schmitz J, Owyang A, Oldham E, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490, 2005. (Pubitemid 41587888)
2. Baekkevold ES, Roussigne M, Yamanaka T, et al: Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163: 69-79, 2003. (Pubitemid 36759592)
3. Carriere V, Roussel L, Ortega N, etal: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104: 282-287, 2007. (Pubitemid 46068023)
4. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA and Massa PT: Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 84: 631-643, 2008.
5. Kuchler AM, Pollheimer J, Balogh J, et al: Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. AmJPathol 173: 1229-1242, 2008.
6. Iikura M, Suto H, Kajiwara N, et al: IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 87: 971-978, 2007. (Pubitemid 47429189)
7. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G and Gabay C: Interleukin(IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40: 216-225, 2007. (Pubitemid 350213434)
8. Kakkar R and Lee RT: The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7: 827-840, 2008.
9. Cayrol C and Girard JP: The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 106: 9021-9026, 2009.
10. Moussion C, Ortega N and Girard JP: The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 3: e3331, 2008.
11. Leung BP, Xu D, Culshaw S, McInnes IB and Liew FY: A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 173: 145-150, 2004. (Pubitemid 38797335)
12. Xu D, Jiang HR, Kewin P, et al: IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 105: 10913-10918, 2008.
13. Palmer G, Talabot-Ayer D, LamacchiaC, et al: Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 60: 738-749, 2009.
14. Verri WA Jr, Souto FO, Vieira SM, et al: IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 69: 1697-1703, 2010.
15. Matsuyama Y, Okazaki H, Tamemoto H, et al: Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 37: 18-25, 2010.
16. Kaieda S, Shin K, Nigrovic PA, et al: Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J Biol Chem 285: 21478-21486, 2010.
17. Palmer G, Trolliet S, Talabot-Ayer D, Mezin F, Magne D and Gabay C: Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1). Cytokine 31: 153-160, 2005. (Pubitemid 40910232)
18. Sharma S, Kulk N, Nold MF, et al: The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 180: 5477-5482, 2008.
19. Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988. (Pubitemid 18091653)
20. Zimmermann T, Kunisch E, Pfeiffer R, et al: Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture - primary culture cells markedly differ from fourth-passage cells. Arthritis Res 3: 72-76, 2001. (Pubitemid 32223808)
21. Hirth A, Skapenko A, Kinne RW, Emmrich F, Schulze-Koops H and Sack U: Cytokine mRNA and protein expression in primary-culture and repeated-passage synovial fibroblasts from patients with rheumatoid arthritis. Arthritis Res 4: 117-125, 2002. (Pubitemid 34257345)
22. Swaroop N, Chen F, Wang L, Dokka S, Toledo D and Rojanasakul Y: Inhibition of nuclear transcription factor-kappaB by specific IkappaB kinase peptide inhibitor. Pharm Res 18: 1631-1633, 2001. (Pubitemid 33022422)
23. Glass DB, Cheng HC, Mende-Mueller L, Reed J and Walsh DA: Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. J Biol Chem 264: 8802-8810, 1989. (Pubitemid 19151602)
24. Alsalameh S, Amin RJ, Kunisch E, Jasin HE and Kinne RW: Preferential induction of prodestructive matrix metalloproteinase-1 and proinflammatory interleukin 6 and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts via tumor necrosis factor receptor-55. J Rheumatol 30: 1680-1690, 2003. (Pubitemid 36962443)
25. Kunisch E, Gandesiri M, Fuhrmann R, Roth A, Winter R and Kinne RW: Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis 66: 1043-1051, 2007. (Pubitemid 47122317)
26. Pohlers D, Beyer A, Koczan D, Wilhelm T, Thiesen HJ and Kinne RW: Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 9: R59, 2007.
27. Pretzel D, Pohlers D, Weinert S and Kinne RW: In vitro model for the analysis of synovial fibroblast-mediated degradation of intact cartilage. Arthritis Res Ther 11: R25, 2009.
28. Carruth LM, Demczuk S and Mizel SB: Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor. J Biol Chem 266: 12162-12167, 1991. (Pubitemid 21907072)
29. Siders WM, Klimovitz JC and Mizel SB: Characterization of the structural requirements and cell type specificity of IL-1 alpha and IL-1 beta secretion. J Biol Chem 268: 22170-22174, 1993. (Pubitemid 23320731)
30. Brennan FM and McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545, 2008.
31. Grimbacher B, Aicher WK, Peter HH and Eibel H: TNF-alpha induces the transcription factor Egr-1, pro-inflammatory cytokines and cell proliferation in human skin fibroblasts and synovial lining cells. Rheumatol Int 17: 185-192, 1998. (Pubitemid 28122003)
32. Kitasato H, Noda M, Akahoshi T, et al: Activated Ras modifies the proliferative response of rheumatoid synovial cells to TNF-alpha and TGF-alpha. Inflamm Res 50: 592-597, 2001. (Pubitemid 34028323)
33. Aupperle K, Bennett B, Han Z, Boyle D, Manning A and Firestein G: NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 166: 2705-2711, 2001. (Pubitemid 32173511)
34. Takada Y, Ichikawa H, Pataer A, Swisher S and Aggarwal BB: Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene 26: 1201-1212, 2007.
35. Roussel L, Erard M, Cayrol C and Girard JP: Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 9: 1006-1012, 2008.
36. Funakoshi-Tago M, Tago K, Hayakawa M, et al: TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal 20: 1679-1686, 2008.
37. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N and Dahinden CA: Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113: 1526-1534, 2009.
38. Suzukawa M, Iikura M, Koketsu R, et al: An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 181: 5981-5989, 2008.
39. Bufler P, Gamboni-Robertson F, Azam T, Kim SH and Dinarello CA: Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 381: 503-510, 2004. (Pubitemid 38969696)